Father of the Bone Marrow Transplant Dies at 92

Dr. E. Donnall Thomas, the physician who was awarded a Nobel Prize for demonstrating that a bone marrow transplantation could successfully treat patients with lymphoma and leukemia, has died in Seattle at the age of 92.

Dr. Thomas, a faculty member at Fred Hutchinson Cancer Research Center going back to 1974, first conceived of the idea of a bone marrow transplantation as a means of treating patients with blood cancers who otherwise had nowhere else to turn back in the 1950s. But it would require several years and many unfortunate problems before he would see some success.

When Dr. Thomas began to use matched tissue typing as well as drugs to suppress the immune response, he began to overcome the criticism he was getting from the medical community, which claimed the procedure was doing nothing but hurting people.

He and his team completed the first matched sibling donor transplant for a patient with leukemia in 1969, an accomplishment followed up in 1977 by completing the first transplant from an unrelated donor.

For his work, he and Dr. Joseph Murray—a pioneer in the transplantation of kidneys—received the 1990 Nobel Prize in Physiology or Medicine.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap